Mary C Cambou1, Raphael J Landovitz2,3. 1. David Geffen School of Medicine, University of California, Los Angeles, CA, USA. MCambou@mednet.ucla.edu. 2. David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 3. UCLA Center for Clinical AIDS Research & Education (CARE), Division of Infectious Diseases, University of California, Los Angeles, CA, USA.
Abstract
PURPOSE OF REVIEW: Combination antiretroviral therapy (cART) has had dramatic effects on morbidity and mortality for persons living with HIV (PLWH). Despite significant progress in treatment efficacy, tolerability, and reducing pill burden, new agents are needed to address issues of resistance, drug-drug interactions, end organ disease, and adherence. This review covers novel ART agents recently approved or in development. RECENT FINDINGS: Capsid inhibitors (CAI) demonstrate high potency and potential for extended-duration dosing in pre-clinical trials. While previous maturation inhibitors (MI) were hampered by issues of drug resistance, a recent phase IIa trial for a second-generation MI demonstrated promising antiviral activity. A phase I trial to evaluate a transdermal implant of islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), maintained concentrations above the target pharmacokinetic threshold at 12 weeks. The attachment inhibitor fostemsavir is available in the USA for compassionate use in multi-drug-resistant (MDR) HIV. New antiretroviral agents show promise for both extended-duration dosing and MDR HIV.
PURPOSE OF REVIEW: Combination antiretroviral therapy (cART) has had dramatic effects on morbidity and mortality for persons living with HIV (PLWH). Despite significant progress in treatment efficacy, tolerability, and reducing pill burden, new agents are needed to address issues of resistance, drug-drug interactions, end organ disease, and adherence. This review covers novel ART agents recently approved or in development. RECENT FINDINGS: Capsid inhibitors (CAI) demonstrate high potency and potential for extended-duration dosing in pre-clinical trials. While previous maturation inhibitors (MI) were hampered by issues of drug resistance, a recent phase IIa trial for a second-generation MI demonstrated promising antiviral activity. A phase I trial to evaluate a transdermal implant of islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), maintained concentrations above the target pharmacokinetic threshold at 12 weeks. The attachment inhibitor fostemsavir is available in the USA for compassionate use in multi-drug-resistant (MDR) HIV. New antiretroviral agents show promise for both extended-duration dosing and MDR HIV.
Authors: Craig S Pace; Marshall W Fordyce; David Franco; Chia-Ying Kao; Michael S Seaman; David D Ho Journal: J Acquir Immune Defic Syndr Date: 2013-01-01 Impact factor: 3.731
Authors: R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: Stephanie E Barrett; Ryan S Teller; Seth P Forster; Li Li; Megan A Mackey; Daniel Skomski; Zhen Yang; Kerry L Fillgrove; Gregory J Doto; Sandra L Wood; Jose Lebron; Jay A Grobler; Rosa I Sanchez; Zhen Liu; Bing Lu; Tao Niu; Li Sun; Marian E Gindy Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Patrick F Smith; Abayomi Ogundele; Alan Forrest; John Wilton; Karl Salzwedel; Judy Doto; Graham P Allaway; David E Martin Journal: Antimicrob Agents Chemother Date: 2007-07-16 Impact factor: 5.191
Authors: Stephen R Yant; Andrew Mulato; Derek Hansen; Winston C Tse; Anita Niedziela-Majka; Jennifer R Zhang; George J Stepan; Debi Jin; Melanie H Wong; Jill M Perreira; Eric Singer; Giuseppe A Papalia; Eric Y Hu; Jim Zheng; Bing Lu; Scott D Schroeder; Kevin Chou; Shekeba Ahmadyar; Albert Liclican; Helen Yu; Nikolai Novikov; Eric Paoli; Daniel Gonik; Renee R Ram; Magdeleine Hung; William M McDougall; Abraham L Brass; Wesley I Sundquist; Tomas Cihlar; John O Link Journal: Nat Med Date: 2019-09-09 Impact factor: 53.440
Authors: Beata Nowicka-Sans; Tricia Protack; Zeyu Lin; Zhufang Li; Sharon Zhang; Yongnian Sun; Himadri Samanta; Brian Terry; Zheng Liu; Yan Chen; Ny Sin; Sing-Yuen Sit; Jacob J Swidorski; Jie Chen; Brian L Venables; Matthew Healy; Nicholas A Meanwell; Mark Cockett; Umesh Hanumegowda; Alicia Regueiro-Ren; Mark Krystal; Ira B Dicker Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: Javier Morales-Ramirez; Johannes R Bogner; Jean-Michel Molina; Johan Lombaard; Ira B Dicker; David A Stock; Michelle DeGrosky; Margaret Gartland; Teodora Pene Dumitrescu; Sherene Min; Cyril Llamoso; Samit R Joshi; Max Lataillade Journal: PLoS One Date: 2018-10-23 Impact factor: 3.240
Authors: Amarendra Pegu; Ling Xu; Megan E DeMouth; Giulia Fabozzi; Kylie March; Cassandra G Almasri; Michelle D Cully; Keyun Wang; Eun Sung Yang; Joana Dias; Christine M Fennessey; Jason Hataye; Ronnie R Wei; Ercole Rao; Joseph P Casazza; Wanwisa Promsote; Mangaiarkarasi Asokan; Krisha McKee; Stephen D Schmidt; Xuejun Chen; Cuiping Liu; Wei Shi; Hui Geng; Kathryn E Foulds; Shing-Fen Kao; Amy Noe; Hui Li; George M Shaw; Tongqing Zhou; Constantinos Petrovas; John-Paul Todd; Brandon F Keele; Jeffrey D Lifson; Nicole A Doria-Rose; Richard A Koup; Zhi-Yong Yang; Gary J Nabel; John R Mascola Journal: Cell Rep Date: 2022-01-04 Impact factor: 9.423
Authors: Linda-Gail Bekker; Benjamin Brown; Dvora Joseph-Davey; Kathrine Gill; Michelle Moorhouse; Sinead Delany-Moretlwe; Landon Myer; Catherine Orrell; Kevin Rebe; W D Francois Venter; Carole L Wallis Journal: South Afr J HIV Med Date: 2020-12-10 Impact factor: 2.744